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Differences in virion RNA dimer stability between mature and protease-defective (immature) forms of
human immunodeficiency virus type 1 (HIV-1) suggest that maturation of the viral RNA dimer is regulated by
the proteolytic processing of the HIV-1 Gag and Gag-Pol precursor proteins. However, the proteolytic pro-
cessing of these proteins occurs in several steps denoted primary, secondary, and tertiary cleavage events and,
to date, the processing step associated with formation of stable HIV-1 RNA dimers has not been identified. We
show here that a mutation in the primary cleavage site (p2/nucleocapsid [NC]) hinders formation of stable
virion RNA dimers, while dimer stability is unaffected by mutations in the secondary (matrix/capsid [CA],
p1/p6) or a tertiary cleavage site (CA/p2). By introducing mutations in a shared cleavage site of either Gag or
Gag-Pol, we also show that the cleavage of the p2/NC site in Gag is more important for dimer formation and
stability than p2/NC cleavage in Gag-Pol. Electron microscopy analysis of viral particles shows that mutations
in the primary cleavage site in Gag but not in Gag-Pol inhibit viral particle maturation. We conclude that
virion RNA dimer maturation is dependent on proteolytic processing of the primary cleavage site and is
associated with virion core formation.
The human immunodeficiency virus type 1 (HIV-1) positive-
stranded RNA genome, which forms a dimer within the virion,
is part of a ribonucleoprotein (RNP) complex encased in a
capsid shell and enveloped in the viral membrane studded with
glycoproteins. HIV-1 virions are initially produced as imma-
ture particles that undergo maturation during or shortly after
budding from the plasma membrane (12). The immature virion
does not contain the internal core structure found in mature
virions but instead has a thick electron-dense spherical struc-
ture directly underneath the virion envelope (31). Conversion
of immature to mature virions is termed maturation, and it
requires proteolytic cleavage of the HIV-1 structural polypro-
teins Gag and Gag-Pol by viral protease (PR). This proteolysis
is initiated at the membrane of the infected cell during virion
budding and release and improves the release of progeny vi-
ruses (30).
The main structural proteins of retroviruses are synthesized
as a single polyprotein, which in the case of HIV-1 is called
Gag or Pr55gag (48). The viral replication enzymes PR, reverse
transcriptase (RT), and integrase (IN) are synthesized as a
second polyprotein, Gag-Pol, which is N terminally colinear
with Gag and is derived from ribosomal frameshifting at a rate
of 5% (28). These polyproteins associate with other viral pro-
teins and genomic RNA to form the immature virion. Within
the virion, Gag is cleaved into matrix (MA), capsid (CA),
nucleocapsid (NC), p6, and two spacer peptides, p2 and p1.
Gag-Pol also contains MA and CA but its C-terminal cleavage
products are p2, NC, transframe protein (TF), PR, RT, and IN
(Fig. 1). The substrate specificity and the kinetics of cleavage
by HIV-1 protease have previously been described (26, 41, 44).
Cleavage sites differ in their amino acid composition, but in all
cases the minimum substrate length required to permit cleav-
age by PR is roughly 7 amino acids (aa) (7). Many of these sites
are distributed close to the CA region encoded by Pr55gag.
Cleavage of CA from its neighbors within Gag polyprotein is
necessary for core condensation and conical capsid shell for-
mation during virion maturation (50, 51).
Cleavage of Gag and Gag-Pol is essential for maturation and
HIV-1 infectivity; mutation or inhibition of PR abolishes pro-
duction of infectious viruses (42, 51). The order and contribu-
tion of individual cleavages have been studied in a cell-free
system, as well as in tissue culture systems. These studies have
revealed that in HIV-1, the proteolytic processing of Gag oc-
curs in an orderly fashion with primary, secondary, and tertiary
sites being sequentially cleaved by PR (Fig. 1) (43, 51). Gag
proteolysis is thought to be regulated, in part, by the cleavage
of the p2 spacer peptide (43). This peptide has also been shown
in a cell-free system to act as the morphologic switch region
during maturation of the virus particle (19). Moreover, using
the protease inhibitor Ro 31-8959, Lindhofer et al. (35) have
observed production of intermediate products via autolytic
processing of Gag-Pol precursor protein, suggesting that the
cleavage of Gag-Pol also occurs in a defined sequence (Fig. 1).
During viral particle maturation, the packaging and rear-
rangement of the genomic RNA rely on RNA-protein inter-
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actions (3, 36). A chaperone activity for Gag protein has been
described (16). In addition, the NC sequence within Gag pro-
tein binds to genomic RNA and facilitates RNA packaging (5,
13, 23). In HIV-1, at least one zinc finger of the NC is required
for efficient RNA packaging to occur (4, 5, 11). Mutations in
the first zinc finger markedly reduce genomic RNA packaging
into virions, while mutations in the second zinc finger only
decrease RNA packaging by 30% (22).
Genomic RNA packaged in HIV-1 virions is dimeric. The
inactivation of viral protease decreases the stability of the
RNA dimer, suggesting that proteolytic processing and RNA
dimer maturation are interrelated (18, 19). In addition, dele-
tion of the dimer initiation sequence, a region essential for
RNA dimerization, results in delayed processing of p2 from
CA and is associated with a reduction in virus infectivity (33,
34). Other authors have suggested that noncoding viral RNA
leader sequences may also accelerate proteolytic processing of
the precursor proteins (47; for a review, see reference 50). In
other retroviruses, e.g., Rous sarcoma virus, mutation of NC
leads to the production of noninfectious Rous sarcoma virus,
which contains unstable virion RNA dimers (39; for a review,
see reference 31). Moreover, whether in its mature (p7) or
precursor (p15) form, HIV-1 NC induces maturation of retro-
viral dimeric RNA in a cell-free system (16, 17, 40). From these
studies it appears likely that the NC sequence within Gag or
the mature NC itself stabilizes HIV-1 RNA dimers. However,
the involvement of HIV-1 NC in RNA dimerization during
viral assembly has not been directly examined.
We report here that a mutation in the primary cleavage site
(p2/NC) of the HIV-1 genome which prevents the cleavage of
CA-p2 from NC markedly decreases genomic RNA dimer sta-
bility. Mutations in the secondary (MA/CA and p1/p6) and
tertiary (CA/p2) cleavage sites do not alter RNA dimer stabil-
ity, suggesting that stable RNA dimer formation occurs either
simultaneously or immediately after proteolysis at the primary
cleavage site of Gag. In addition, using a cotransfection system,
we show that for HIV-1 the cleavage of the p2/NC site in Gag
is more important than cleavage of the same site in Gag-Pol for
RNA dimerization and the condensation of the virion core.
This study suggests that the free N terminus of NC is likely to
be important for virion RNA dimer maturation and virion core
capsid formation.
MATERIALS AND METHODS
DNA plasmids. The cleavage site HIV-1 mutants MA/CA, p1/p6, and CA/p2,
containing a P1 Ile substitution that inhibits cleavage, were previously described
by Pettit et al. (42). A full-length HIV-1 proviral clone, NL4.3, was used as a
control. The single cleavage site mutant CA2 (p2/NC), double cleavage site
mutant CA5 (CA/p2 and a CA cryptic site mutation), and triple cleavage site
mutant CA6 (p2/NC-CA/p2-cryptic site mutation) have been previously de-
scribed by Wiegers et al. (51; see Table 1 for details). For the cotransfection
study, the full-length wild-type (WT) HIV-1 plasmid used was HXB2-BH10 (49).
The Gag-Pol expression plasmid (GP) was constructed using PCR stitch mu-
tagenesis as previously described (37). The frameshift mutation in GP allows
continuous expression of Gag-Pol and bypasses the Gag termination codon. The
GagUAA (G) plasmid was also constructed by using PCR stitch mutagenesis in
order to introduce a stop codon within the frame of the Pol protein. This stop
codon insertion terminates Gag-Pol synthesis in aa 13 of PR. As a result, this
FIG. 1. Schematic representation of sequential proteolytic processing of HIV-1 Gag (G) and Gag-Pol (GP) precursor proteins by viral PR and
the initial proteolysis rate of the primary (1°), secondary (2°), and tertiary (3°) cleavage sites of Gag (slower) adapted from Pettit et al. (42, 43).
The scissors symbol represents corresponding locations cut by PR in HIV-1. In this study, constructs containing mutations that do not allow the
processing of the primary (p2/NC), secondary (MA/CA and p1/p6), and tertiary (CA/p2) cleavage sites, from two different sources, were analyzed
for their protein profiles and genomic RNA dimer maturation.
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mutation does not allow the synthesis of full-length Gag-Pol and the expression
of a functional PR. HXB2-BH10 was used for the construction of both the G and
the GP clones.
The DNA regions containing mutations within the primary cleavage site (p2/
NC) or in primary and late cleavage sites (p2/NC and CA/p2) were removed from
CA2 or CA6 mutants and cloned into the G and GP plasmids via SpeI and ApaI
restriction enzyme sites.
Virus production. The production of WT and mutant HIV-1 viral particles was
achieved by transfection of 10 g of proviral DNA of each plasmid into 293T
cells using a calcium phosphate method as previously described (29).
The production of HIV-1 particles containing mutations in the cleavage sites
of Gag or Gag-Pol was achieved by cotransfection of either intact G or GP DNA
plasmids with the mutated counterparts maintaining the 20:1 GagUAA/GP ratio
(10 g of G to 0.5 g of GP) found in natural infections. Cotransection of intact
G and GP vectors resulted in the 20:1 Gag/Gag-Pol protein expression ratio in
the virus-producing cells. An enhanced green fluorescent protein (EGFP; Clon-
tech) reporter plasmid (2 g) was added to the DNA mixture to determine the
transfection efficiency.
Supernatants were collected 36 h posttransfection and centrifuged for 30 min
at 4°C and 3,000 rpm (Beckman) to remove cellular debris. The clarified super-
natants were either frozen at 70°C or used immediately for further analysis.
Cells were washed twice with either phosphate-buffered saline (PBS) or 1
Tris-buffered saline (TBS) buffer (50 mM Tris, pH 7.4; 150 mM NaCl), followed
by protein extraction using lysis buffer containing 1 TBS, 10 l of Nonidet
P-40/ml, 20 mM phenylmethylsulfonyl fluoride, 1 M pepstatin, and 1 M
leupeptin. Cell lysates were collected and stored at 20°C for later use.
Intracellular viral protein analysis. Cell lysates were rapidly frozen and
thawed three times to weaken the cellular membrane. Cell debris was subse-
quently removed by centrifugation for 30 min at 4°C at 3,000 rpm (Beckman).
The transfection efficiency of the samples was determined by measuring the level
of EGFP from the reporter plasmid using a Bio Imaging Analyzer (Fuji Photo
Film Co.). Intracellular viral protein from each sample normalized for equivalent
levels of EGFP was mixed with 3 l of sample buffer (100 mM Tris, pH 6.8; 3%
sodium dodecyl sulfate [SDS]; 33% glycerol; 0.03% bromophenol blue), dena-
tured for 10 min at 95°C, and resolved by SDS–10% polyacrylamide gel electro-
phoresis (PAGE). Resolved proteins were transferred to a nitrocellulose mem-
brane (Amersham) for Western blot analysis. The membrane was blocked for 2 h
in 3% casein dissolved in 2 TBS containing 0.3% Tween 20 (TBST) and probed
overnight with pooled HIV-1-seropositive patient sera or anti-p24/CA monoclo-
nal antibody (MAb) (NEN). After three washes with 1 TBST buffer the mem-
brane was incubated with anti-human or anti-mouse horseradish peroxidase-
conjugated secondary antibody (Dako) for 2 h at room temperature. An
enhanced chemiluminescence (ECL) technique was used for detection of HIV-1
proteins present in the intracellular lysates (Amersham). Results were visualized
by autoradiography.
Virion purification and protein analysis. Clarified supernatants from trans-
fected cells were purified and concentrated by ultracentrifugation through a 20%
sucrose cushion in TE buffer (10 mM Tris, 1 mM EDTA; pH 8.0) by using a
Beckman L-90 ultracentrifuge (SW41 rotor) at 35,000 rpm for 1 h at 4°C. Pellets
were resuspended in 50 l of TBS lysis buffer.
Analysis of virion protein profile. Equal amounts of virion protein normalized
by dot blotting (46) from each sample were mixed with 3 l of sample buffer
containing 5 mM -mercaptoethanol and heated for 10 min at 95°C. Virion
proteins for analysis of the HIV-1 protein pattern and detection of p24-CA were
then resolved by SDS–10% PAGE as described above. The resolved virion
protein samples were transferred onto nitrocellulose membranes for Western
blot analysis as described above. For the detection of p7-NC protein, normalized
and denatured virion proteins were resolved in a 16.5% Tricine gel (Bio-Rad)
under electrophoresis conditions with a Tris-Tricine buffer. Resolved proteins
were transferred to a polyvinylidene difluoride membrane. An ECL technique
was used for the detection of mature and intermediate NC proteins present in
the virions (Amersham). Results were visualized by autoradiography.
Analysis of virion RNA dimerization. Virion pellets were resuspended in 500
l of dimeric RNA lysis buffer (10 mM Tris [pH 7.5], 1 mM EDTA, 1% SDS, 50
mM NaCl, and 10 U of proteinase K), lysed for 30 min at room temperature,
phenol-chloroform extracted, and isolated for melting-curve analysis as previ-
ously described (18, 19).
Similar amounts of genomic RNA were used to analyze the stability of the
virion RNA dimer in each preparation by heating the samples at the indicated
temperatures for a period of 10 min, followed by a quick chill in ice. Heat-
denatured dimeric and monomeric RNAs were separated by electrophoresis in a
1% native agarose gel in 0.5 Tris-borate-EDTA buffer and transferred over-
night onto a nitrocellulose (Hybond N) membrane (Amersham). The membrane
containing the RNA samples was air dried for 2 h at room temperature and
exposed to UV light for 90 s to allow cross-linking to occur. The membrane was
blocked for 1 h at 42°C with 10 ml of hybridization buffer (30). Dimeric and
monomeric RNAs were incubated overnight with a 32P-labeled riboprobe, which
is complementary to the 5 end of the HIV-1 genomic RNA sequences, as
previously described (46). The riboprobe was synthesized by linearizing the
pGEM7z HIV-1 plasmid with BamHI, followed by T7 RNA polymerase-TP
(NEN). After the probing, the membrane was washed once for 30 min with 1
SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.1% SDS buffer and
twice for 30 min with 0.2 SSC–0.1% SDS buffer. The results were visualized by
autoradiography. Migration of WT RNA as well as RNA derived from the
cotransfection of the intact G and GP plasmids served as controls to determine
the effect of cleavage site mutations on RNA dimerization.
TSEM. Transfected 293T cells were harvested at appropriate times posttrans-
fection and processed for thin-section electron microscopy (TSEM) as described
previously (32). Briefly, cells were washed in cacodylate (CAC) buffer (pH 7.2)
and pelleted by centrifugation at 500  g for 5 min. The cell pellet was then fixed
in 2% glutaraldehyde-CAC buffer for 1 h at 4°C. After several washes in CAC
buffer, the pellet underwent secondary fixation in 1% osmium tetroxide-CAC
buffer for 1 h at 4°C. Pellets were rinsed in distilled water, dehydrated in graded
ethanol, cleared in propylene oxide, and embedded in Spurr resin (Ladd Re-
search, Inc., Williston, Vt.). Ultrathin sections with silver and gold interference
color were mounted on uncoated 200-mesh copper grids and stained with uranyl
acetate and lead citrate. The sections were then examined by using a CM12
electron microscope (Philips, Eindhoven, The Netherlands).
RESULTS
Mutations in the Gag and Gag-Pol cleavage sites of HIV-1
inhibit proteolysis by PR. Cells transfected with either the WT,
NL4.3, or the cleavage site mutants of this full-length molec-
ular clone had protein profiles similar to those previously de-
scribed (51; S. Pettit and R. Swanstrom, unpublished data).
Virion protein profiles of cleavage site mutants probed with
anti-p24 MAb were in agreement with previous reports (51;
Pettit and Swanstrom, unpublished) (Fig. 2). Briefly, the WT
(NL4.3) and the p1/p6 mutant expressed similar levels of CA-
p24 (Fig. 2, panel i/A, lanes 1 and 2). Mutant MA/CA yielded
an MA-CA intermediate product with a relative molecular
mass of 39 kDa (Fig. 2, panel i/A, lane 3) as a result of a point
mutation that hinders the release of the N terminus of the
capsid protein from matrix. As previously observed (51; Pettit
and Swanstrom, unpublished), mutants CA/p2 and CA5
yielded similar levels of a CA-p2 intermediate (CA extended
by 14 aa) and no mature CA-p24 (Fig. 2, panel i/A, lane 4, and
panel i/B, lane 2). The CA2 mutant expressed less CA-p24 and
a CA-NC protein complex (Fig. 2, panel i/B, lane 1) due to
inefficient processing of the N terminus of NC. This resulted in
the formation of a p33 CA-p2-NC processing intermediate.
TABLE 1. Cleavage site mutants used in this studya
Mutant Cleavage site(s) mutated Source of mutants and/orreferences
pNL 4.3 NIH reagent program
MA/CA Secondary Pettit and Swanstrom,
unpublished
CA/p2 Tertiary Pettit and Swanstrom,
unpublished
p1/p6 Secondary Pettit and Swanstrom,
unpublished
CA2 Primary (p2/NC) Wiegers et al. (36)
CA5 Tertiary (CA/p2 and cryptic site) Wiegers et al. (36)
CA6 Primary, tertiary, and cryptic site
a For detailed information about the construction of the mutants see the
references cited in column 3, and for sequential classification of sites see Fig. 1.
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The presence of CA-p24 suggests that the p2/NC mutation
hindered but did not block the release of an N-terminally
extended NC protein from the CA-p2-NC (p25) intermediate.
As expected, no CA-p24 protein was detected for CA6 (Fig. 2,
panel i/B, lane 3) due to point mutations in the primary site
(p2/NC), the tertiary site (CA/p2), and a further cryptic cleav-
age site. These mutations completely blocked the release of the
NC from the CA-p2 protein complex, resulting in virions con-
taining predominantly a CA-p2-NC processing intermediate.
WT, p1/p6, MA/CA, CA/p2, and CA5 mutants expressed
similar levels of p7-NC in the virions (Fig. 2iiA, lanes 1 to 4,
and iiB, lane 2). The mutation in the p2/NC cleavage site
resulted in the release of a p9 (NC-p2) intermediate and no
mature p7-NC, whereas combined mutations in the p2/NC and
CA/p2 cleavage sites blocked processing of p2 from NC and
CA from p2, giving rise to a p33 protein complex (Fig. 2iiB,
lanes 1 and 3, respectively). The p33 protein complex was also
observed in the p2/NC mutant virions, supporting the results
obtained from the detection of CA-p24 described above.
A primary cleavage site mutation in Gag/Gag-Pol leads to
reduced stability of the HIV-1 RNA dimers. Dimeric RNA was
observed in all mutant viruses, regardless of the nature of the
mutation introduced in the full-length HIV-1 genome (Fig. 3).
However, the stability of the dimeric RNA was markedly re-
duced when mutations were introduced in the primary cleav-
age site alone (CA2, Fig. 3B) or in both primary and tertiary
cleavage sites (CA6, Fig. 3B). In these preparations, virion
RNA dimers began to dissociate into monomers at tempera-
tures as low as 42°C; in fact, almost all of the virion RNAs were
detected as monomers when the samples were heated to 48°C.
In contrast, HIV-1 mutants containing mutations in secondary
(MA/CA and p1/p6, Fig. 3A) or tertiary proteolytic cleavage
sites (CA/p2, Fig. 3A, and CA5, Fig. 3B) exhibited the same
RNA dimer stability as that of the WT counterpart (NL 4.3,
Fig. 3A); in these preparations, virion RNA dimers could still
be detected at higher dissociation temperatures (48 to 50°C).
Cleavage site mutations in Gag affect the HIV-1 virion pro-
tein profiles much more than the same mutations in Gag-Pol.
We have shown in Fig. 3 that a single (p2/NC) or a triple
mutation (p2/NC, CA/p2, and in a cryptic site) block full pro-
cessing of CA and NC proteins and destabilize virion RNA
dimers. The relative contribution to this effect of the respective
cleavage sites in Gag versus the corresponding sites in Gag-Pol
is unknown. To answer this question, we have introduced ei-
ther the p2/NC cleavage site mutation (CA2) or the combined
p2/NC, CA/p2, and a cryptic site mutation (CA6) into either G
or the GP expression vector (Fig. 4). The resultant DNA con-
structs were designated GCA2, GCA6, GPCA2, and GPCA6, re-
spectively. The Gag (G) expression construct was then trans-
fected with GPCA2 alone or in combination with GPCA6
mutant, while the Gag-Pol (GP) expression construct was
transfected with GCA2 alone or in combination with GCA6.
Since cotransfection of the WT Gag and WT Gag-Pol ex-
pression vectors (G/GP) produced viral particles with the same
intracellular viral protein and virion protein profiles as WT
virus (Fig. 5, lanes b), G/GP viruses were used as controls in all
of the subsequent cotransfection studies (Fig. 5, lanes 1). In-
tracellular viral proteins and virion proteins derived from cells
cotransfected with GCA2/GP constructs yielded levels of CA-
p24 and CA-NC that were similar to those observed for the
CA2 mutation in a proviral clone (Fig. 5, lanes 4), while
G/GPCA2 intracellular and virion proteins yielded undetect-
able levels of CA-NC (Fig. 5, lanes 2). Accordingly, almost
exclusively, CA-NC was observed upon cotransfection of GCA6
/GP (Fig. 5, lanes 5), while significantly lower levels of intra-
cellular viral protein and virion CA-NC protein complex were
yielded upon cotransfection with G/GPCA2 or G/GPCA6 (Fig. 5,
lanes 2 and lanes 3, respectively).
The primary cleavage site in Gag is more important for
RNA dimerization than the corresponding site in Gag-Pol.
Genomic RNA isolated from viral particles derived from co-
transfection of plasmids G and GP was dimeric and exhibited
FIG. 2. Impact of mutations within the primary, secondary, and late-proteolytic processing cleavage sites of HIV-1 on the protein composition
of purified virions. Viral proteins were semiquantified by Western blot analysis. Purified virions were resolved by using 10% Tris-glycine
SDS-PAGE (i) and by 16.5% Tris-Tricine SDS-PAGE (ii). Resolved proteins were probed with anti-p24 MAb or anti-p7 polyclonal antibody with
specific activity to NC protein, as described in Materials and Methods.
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the same stability as virion RNA dimers isolated from WT
NL4.3 virus (compare Fig. 6 and Fig. 3A, respectively).
Genomic RNA isolated from viral particles containing the
primary cleavage site mutation in Gag (GCA2/GP) started to
dissociate into monomers at room temperature, while dimeric
RNA from viral particles containing the corresponding muta-
tion in Gag-Pol (G/GPCA2) was as heat stable as WT G/GP
RNA dimers, with a dissociation temperature of 45 to 48°C
(Fig. 6A and B, respectively). The introduction of the com-
bined mutations in Gag (GCA6/GP) further decreased dimer
stability with more than 50% of the RNA dimers dissociating
into monomers at room temperature (Fig. 6A), while the cor-
responding mutations in Gag-Pol (G/GPCA6) caused a negli-
gible decrease in the dimer stability of the RNA (Fig. 6B).
These results show that the primary cleavage site in Gag-Pol
plays a less important role in dimer RNA stability than the
corresponding site in Gag.
Mutations in the primary cleavage site of Gag (but not in
Gag-Pol) inhibit core formation. Immature (Fig. 7A) and ma-
ture (Fig. 7B) forms of virus detected on or near the surface of
the cells transfected with G/GP DNA constructs were similar
in morphology to their WT HIV-1 counterpart. The G/GP
immature virions were observed as round or ovoid enveloped
particles containing an inner ring and having a hollow appear-
ance (Fig. 7A). In contrast, the mature G/GP virions appeared
as round or ovoid spherical enveloped particles containing a
mature electron-dense core, which appeared cone shaped or
round depending on the angle of sectioning (Fig. 7B). In cells
cotransfected with GCA2/GP (Fig. 7C and D) and GCA6/GP
(Fig. 7E and F) DNA constructs, only immature forms of the
virus were detected; at times, an internal structure similar to
that reported by Hockley et al. (27) was observed within these
immature virions (Fig. 7D and F). In preparations that were
derived from cells cotransfected with G/GPCA2 and G/GPCA6
constructs, both immature (Fig. 7G and I) and mature (Fig. 7H
and J) virions were detected; the ratios of immature to mature
virions in these preparations were similar to those derived
from the G/GP preparation (data not shown). Measurements
of virus particles (Table 2) showed no significant differences
between mutant and WT virions either in the mature or in the
immature form.
FIG. 3. Effects of mutations within the primary, secondary, and late cleavage sites on virion RNA dimerization. The impact of mutations within
proteolytic processing cleavage sites on genomic RNA dimerization was determined by using melting-curve and electrophoretic analysis of WT and
mutant dimers. Virion RNA was resuspended in RNA dimerization buffer and heat denatured for 10 min at the indicated temperatures. Dimers
and monomers were electrophoresed in a 1% native agarose gel and probed with an HIV-1 riboprobe, as described in Materials and Methods. (A)
RNA dimerization analysis of genomic RNA isolated from WT HIV-1 (NL4.3), CA/p2, MA/CA, and p1/p6 mutant virions. (B) RNA dimerization
analysis of genomic RNA isolated from CA2, CA5, and CA6 mutant virions.
FIG. 4. Schematic representation of WT control and G and GP
plasmid DNA used in cotransfections for the production of viral par-
ticles containing mutations in cleavage sites in either Gag or Gag-Pol.
WT HXB2-BH10 was used for the construction of both the GagUAA
(G) and the GP clones. The G plasmid was constructed by using PCR
stitch mutagenesis in order to introduce a stop codon within the frame
of the Pol protein. The Gag-Pol expression plasmid (GP) has been
previously described (37). The frameshift mutation introduced here
allows continuous expression of Gag-Pol and bypasses the Gag termi-
nation codon. The DNA regions containing mutations within the pri-
mary cleavage site (p2/NC) or in primary and tertiary cleavage sites
(p2/NC and CA/p2) were removed from CA2 or CA6 mutants and
cloned into the G and GP plasmids via SpeI and ApaI restriction
enzyme sites, respectively. The resultant mutants were termed GCA2,
GCA6, GPCA2, and GPCA6 (see also Table 2). The G plasmid was then
cotransfected with either GPCA2 alone or in combination with GPCA6
while the GP plasmid was cotransfected with either GCA2 alone or in
combination with GCA6 in 293T cells.
9160 SHEHU-XHILAGA ET AL. J. VIROL.
DISCUSSION
This study provides direct evidence that the sequential pro-
cessing of Gag and Gag-Pol proteins by viral protease regulates
genomic RNA maturation (i.e., RNA dimerization and stabil-
ity). Virion RNA dimer maturation was dependent on the
proteolysis of the primary cleavage site of Gag but indepen-
dent of the processing of the secondary and tertiary cleavage
sites. Furthermore, the cleavage of the p2/NC site in Gag but
not Gag-Pol was critical for the formation of stable RNA
dimers and condensation of the virion core. Our study supports
and extends previous reports (1, 2, 14, 16, 17, 40) showing that
genomic RNA dimer formation is under the control of Gag
protein and that formation of N terminally cleaved NC is
required for the generation of stable RNA dimers.
The cleavage of the p2/NC site in HIV-1 is critical for virion
RNA dimer stability. Previous studies have suggested that Gag/
Gag-Pol PR processing may influence RNA dimerization. Fu
and coworkers (18, 19) have shown that PR activity is required
for RNA dimer stability. Our study shows that mutations of the
primary (p2/NC) Gag/Gag-Pol cleavage site dramatically de-
crease the stability of virion RNA dimers. In contrast, RNA
dimer stability remains unaffected by mutations in the second-
ary and tertiary cleavage sites. Our findings suggest that the
p2-NC intermediate found in virions as a result of altered
processing in the p2/NC site is unable to substitute for fully
processed NC in the formation of stable virion RNA dimers.
Therefore, the release of the NC protein from p2, thus freeing
the N terminus of the NC protein, is essential for stable
genomic RNA dimer formation. Mature NCp7 has been re-
ported to convert unstable RNA dimers into stable dimers in a
cell free system by interacting with a “kissing loop complex,”
suggesting that NCp7 is an important contributor to RNA
dimer formation (16, 17, 40). A similar observation has also
been made for Moloney murine leukemia virus (MoMLV)-
derived genomic RNA in vitro (8).
We speculate that the interaction between genomic RNA
and an NC intermediate (NC-p1-p6 or p15) is sufficient for the
formation of the dimeric RNA complex. However, the data
suggest that the free N terminus of NC in the context of p15
is critical for the stability of these dimers in vivo and is in
FIG. 5. Effect of a primary or combined primary and late cleavage site mutations within Gag or Gag-Pol on intracellular viral proteins and
virion protein profiles of HIV-1. Intracellular viral proteins were standardized by EGFP, and total virion protein levels were standardized by dot
blot analysis (data not shown). Cotransfected cell lysates (A) and purified virions (see Materials and Methods) (B) were resolved by SDS–10%
PAGE. Resolved proteins were probed using sera from HIV-1-infected individuals, as described in Materials and Methods. Lanes 1, show G/GP
cellular viral proteins and virion protein profiles, respectively. Lanes 2 and lanes 3 show cellular viral proteins and virion protein profiles of mutant
viruses containing a primary CA2 (p2/NC) or a combined primary and late cleavage site mutation CA6 (p2/NC, CA/p2, and a cryptic site mutation)
in Gag-Pol, respectively. Lanes 4 and lanes 5 show cellular viral proteins and virion protein profiles of mutant viruses containing a primary CA2
(p2/NC) or a combined primary and late cleavage site mutation CA6 (p2/NC and CA/p2) in Gag, respectively. Lanes a and lanes b show mock-
and WT-transfected controls. The amounts of WT HIV-1 intracellular and virion proteins were independent of the other proteins tested and were
used in these analysis only to compare HIV-1 protein patterns probed by HIV-1 sera.
FIG. 6. Effect of cleavage site mutations in either Gag or Gag-Pol
on virion RNA dimerization. The impact of mutations in the proteo-
lytic processing cleavage sites within Gag or Gag-Pol on genomic RNA
dimerization was examined by melting curve and electrophoretic anal-
ysis of WT and mutant dimers. Dimers and monomers were electro-
phoresed in 1% native agarose gel and probed with an HIV-1 ribo-
probe, as described in Materials and Methods. (A) RNA dimerization
analysis of genomic RNA isolated from WT (G/GP) and mutant
G/GPCA2 or G/GPCA6 virions. (B) RNA dimerization analysis of
genomic RNA isolated from GCA2/GP and GCA6/GP mutant virions.
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agreement with earlier reports from studies in a cell-free sys-
tem in HIV-1 (2), as well as in MoMLV and Harvey murine
sarcoma virus (17, 38). In another study, Wiegers et al. (51)
have shown that a mutation in the p2/NC site results in the
production of viral particles with immature cores. In addition,
our data suggest that the release of the NC from p2 leads to
RNA maturation. Formation of the RNP complex and con-
densation of the core may follow this step. Taken together,
FIG. 7. Electron microscopic analysis of the mutant viral particles. 293T cells were cotransfected with G/GP (A and B), GCA2/GP (C and D),
GCA6/GP (E and F), GCA2/GP (C and D), and GCA6/GP (E and F). DNA constructs were harvested at 36 h posttransfection and processed for
TSEM as described in Materials and Methods. Both immature (A, G, and I) and mature (B, H, and J) forms of the virus were detected on or near
the surface of the cells transfected with G/GP (control), G/GPCA2, or G/GPCA6. Only immature virions were observed within the GCA2/GP (C and
D) and GCA6/GP (E and F) preparations. (D and F) At times, an internal structure (arrow) within the inner ring of the immature virion was seen.
Two diameters were measured for each viral particle: the longest and shortest diameters, roughly at right angles; the average of the two values was
then taken as the diameter of the viral particle. Bars, 100 nm.
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these results point to a specific role of NC for stable RNA
dimer formation and condensation.
The proteolytic processing of the p2/NC cleavage site in Gag
(but not Gag-Pol) is essential for RNA dimer stability and
virion core formation. We introduced the p2/NC mutation
alone or in combination with the CA/p2 mutation into Gag or
Gag-Pol in order to determine the contribution of these cleav-
age sites in Gag versus Gag-Pol in RNA dimerization and
virion core formation. Our data showed a significant decrease
in CA-NC processing, a dramatic effect in RNA dimer stability
and immature core formation when these mutations were in-
troduced only in Gag. Gag-Pol protein is synthesized as a result
of a 1 frameshifting event resulting in a 20:1 production ratio
of Gag to Gag-Pol in the virus producing cell (28). Therefore,
the ratio of CA and NC derived from Gag protein to CA and
NC derived from Gag-Pol protein at the assembly site of new
virions should correspond with that of the WT Gag/Gag-Pol
ratio (i.e., 20:1). In agreement with this ratio, our data show
that the cleavage of the p2/NC site in Gag is essential for RNA
dimer stability and virion core formation and further suggest
that Gag-Pol proteins contribute only modestly to RNA dimer
stability.
A free N terminus of NC is important for HIV-1 core for-
mation. NC plays diverse roles in HIV-1 replication (13). The
NC domain in the Gag polyprotein facilitates RNA packaging
and is involved in reverse transcription of the viral genome and
possibly at later stages of viral entry (45). A later report has
confirmed that mutations in the basic residues of the N termi-
nal of NC lead to production of viral particles containing de-
fective cores (6). Assembly studies in a cell free system have
demonstrated that the MA-CA-NC complex gives rise to
spherical particles and that the formation of tubular cores (in
Escherichia coli) and conical cores requires only the CA-NC
portion of this protein in the presence of RNA (9, 10, 21, 24,
25). Our results clearly show that in HIV-1, hindering the
processing of the N terminus of NC from CA protein pre-
vented virus maturation. The data demonstrate a strong asso-
ciation between stable RNA dimer formation and core matu-
ration, as well as the importance of the N terminus of NC in
both events. The presence of the RNA dimers within these
immature viral particles, however, suggests that virion genomic
RNA initially dimerizes as a thermally less stable structure.
RNA-NC structural studies have shown that the free amino
terminus of NC resides in the groove of a stem-loop RNA
structure (15) which implies that this aspect of NC-RNA in-
teraction is likely to be an important determinant for virion
RNA packaging. Fuller et al. (20) have suggested that RNA
may function as a scaffold in the formation of the immature
spherical shell. In this case, cleavage of NC leading to the
release of the RNP complex may be required for the morpho-
logic rearrangement as it permits removal of the NC-RNA
scaffold from the condensing core structure. Concomitantly,
freeing the N terminus of NC appears to be necessary and may
be sufficient for the formation of stable RNA dimers, which
can serve as a nucleating event in core maturation.
In summary, our data suggest that correct N-terminal pro-
cessing of NC during viral assembly is a requirement for HIV-1
core formation and high stability of RNA dimers. Once NC is
separated from p2, precise levels of mature CA and NC pro-
teins are generated to form the conical capsid shell and facil-
itate the condensation of the electron-dense RNP core. The
study implies that processing of Gag polyprotein is critical for
RNA dimerization.
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